ALLO-715
 | This article was nominated for deletion. The discussion was closed on 30 May 2022 with a consensus to merge the content into the article B-cell maturation antigen#As a drug target. If you find that such action has not been taken promptly, please consider assisting in the merger instead of re-nominating the article for deletion. To discuss the merger, please use the destination article's talk page. (May 2022) |
ALLO-715 is a CAR-T therapy by Allogene Therapeutics that targets B-cell maturation antigen (BCMA).[1] As of June 2021[update], it is undergoing clinical trials for the treatment of multiple myeloma.[2] On 21 April 2021, Allogene Therapeutics announced that the Food and Drug Administration has granted Regenerative Medicine Advanced Therapy status to ALLO-715.[3]
Medical uses
CAR-T therapies target a patient's own T cells to respond to a particular antigen. Most CAR-T therapies on the market are autologous, that is, they rely on cells extracted from the patient, processed and reinfused.[4] Tisagenlecleucel (Kymriah), for instance, is made by extracting the patient's blood, filtering T cells and processing them.[5] Allogeneic CAR-T therapies may be able to dispense with this process through using TALEN gene editing technology and using T cells from healthy donors, obtained by leukapheresis. ALLO-715 is being investigated at Memorial Sloan Kettering Cancer Center and the Mayo Clinic[6] as part of the UNIVERSAL trial for multiple myeloma, on its own and in conjunction with the selective gamma secretase inhibitor nirogacestat.[2] Initial results of the UNIVERSAL trial were reported in late 2020 to be promising.[7]
References
- ^ Sommer, Cesar; Boldajipour, Bijan; Valton, Julien; Galetto, Roman; Bentley, Trevor; Sutton, Janette; Ni, Yajin; Leonard, Mark; Van Blarcom, Thomas; Smith, Julianne; Chaparro-Riggers, Javier (2018-11-29). "ALLO-715, an Allogeneic BCMA CAR T Therapy Possessing an Off-Switch for the Treatment of Multiple Myeloma". Blood. 132 (Supplement 1): 591. doi:10.1182/blood-2018-99-119227. ISSN 0006-4971.
- ^ a b Allogene Therapeutics (2021-06-23). "A Single-Arm, Open-Label, Phase 1 Study of the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 to Evaluate an Anti-BCMA Allogeneic CAR T Cell Therapy With or Without Nirogacestat in Subjects With Relapsed/Refractory Multiple Myeloma".
{{cite journal}}: Cite journal requires|journal=(help) - ^ "FDA Grants RMAT Designation to ALLO-715 for Relapsed/Refractory Multiple Myeloma". OncLive. Retrieved 2022-05-10.
- ^ Manier, Salomon; Ingegnere, Tiziano; Escure, Guillaume; Prodhomme, Chloé; Nudel, Morgane; Mitra, Suman; Facon, Thierry (2022-01-21). "Current state and next-generation CAR-T cells in multiple myeloma". Blood Reviews. 54: 100929. doi:10.1016/j.blre.2022.100929. ISSN 0268-960X. PMID 35131139. S2CID 246182993.
- ^ Ledford, Heidi (2017-07-01). "Engineered cell therapy for cancer gets thumbs up from FDA advisers". Nature. 547 (7663): 270. Bibcode:2017Natur.547..270L. doi:10.1038/nature.2017.22304. ISSN 1476-4687. PMID 28726836.
- ^ "Safety and Efficacy of ALLO-715 and ALLO-647 BCMA Allogenic CAR T Cells in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)". Mayo Clinic. Retrieved 2022-05-10.
- ^ Taylor, Nick Paul (2020-12-07). "ASH: Allogene's off-the-shelf CAR-T posts 60% response rate in fiercely competitive BCMA field". Fierce Biotech. Retrieved 2022-05-10.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |